Acute pulmonary hypertension after transjugular intrahepatic portosystemic shunt: A potentially deadly but commonly forgotten complication

Gastroenterology Nursing

Volumn 37, Issue 1, 2014, Pages 33-38

  Modock, Jacqueline ^a  

^a Lake Tahoe Regional Hospitalist   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ADVERSE EFFECTS; HUMAN; HYPERTENSION, PULMONARY; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

ACUTE DISEASE; HUMANS; HYPERTENSION, PULMONARY; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC;

EID: 84894155933     PISSN: 1042895X     EISSN: 15389766     Source Type: Journal    
DOI: 10.1097/SGA.0000000000000016     Document Type: Article

References (21)

1. Barst, R., McGoon, M., Torbicki, A., Sitibon, A., Krowka, M., Olschewski, H., & Gaine, S. (2004). Diagnosis and differential assessment of pulmonary arterial hypertension. Journal of the American College of Cardiology, 43(12), S40 - S47.
2. Boyer, T., & Haskal, Z. (2009). AASLD practice guideline update: The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology, 52(1), 1-16.
3. Cartin-Ceba, R., Swanson, K., Iyer, V., Wiesner, R. H., & Krowka, M. J. (2011). Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest, 139(1), 109-114.
4. Centers for Disease Control and Prevention. (1998). Recommendations for prevention and control of Hepatitis C virus. Morbidity and Mortality Weekly Reports, 47(RR-19), 1-39.
5. Centers for Disease Control and Prevention. (2009). Disease burden from viral Hepatitis A, B, and C in the United States. Retrieved from http://www.cdc.gov/injury/wisqars/LeadingCauses.html
6. Centers for Disease Control and Prevention. (2013a, May 28). Hepatitis C information for health professionals. Retrieved from http://www.cdc.gov/ hepatitis/HCV/HCVfaq.htm
7. Centers for Disease Control and Prevention. (2013b, August 8). Ten leading causes of death and injury. Retrieved from http://www.cdc.gov/injury/ wisqars/LeadingCauses.html
8. Fonseca, C., Mota, T., Moais, H., Matias, F., Costa, C., Oliveira, A., & Ceia, F. (2004). The value of the electrocardiogram and chest x-ray for confirming or refuting a suspected diagnosis of heart failure in the community. European Journal of Heart Failure, 6(6), 807-812.
9. Galie, N., Torbicki, A., Barst, R., Dartevelle, P., Haworth, S., Higenbottam, T., & Simmonneau, G. (2009). Guidelines on diagnosis and treatment of pulmonary arterial hypertension. European Heart Journal, 30, 2493-2537.
10. Goldman, L., & Schafer, A. (2012). Goldman's cecil medicine (24th ed.). Philadelphia, PA: Elsevier.
11. Hoeper, M. M., Seyfarth, H. J., Hoeffken, G., Wirtz, H., Spiekerkoetter, E., Pletz, M. W., ⋯ Halank, M. (2007). Experience with inhaled iloprost and bosentan in portopulmonary hypertension. European Respiratory Journal, 30(6), 1096-1102.
12. Janda, S., Shahidi, N., Gin, K., & Swiston, J. (2011). Diagnostic accuracy of echocardiography for pulmonary hypertension: A systematic review and meta-analysis. Heart, 97, 612-622.
13. Kumar, V., Abbas, A., Fausto, N., & Aster, J. (2010). Robbins and cotran pathologic basis of disease (8th ed.) Philadelphia, PA: Elsevier.
14. Kuo, P. C., Johnson, L. B., Plotkin, J. S., Howell, C. D., Bartless, S. T., & Rubin, L. J. (1997). Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation, 63(4), 604-606.
15. McLaughlin, V., Archer, S., Badesch, D., Barst, R., Farber, H., Linder, J., ⋯ Varga, J. (2009). ACCF/AHA 2009 Expert consensus document on pulmonary hypertension. Journal of the American College of Cardiology, 53, 1573-1619.
16. Mettler, F. (2005). Abdominal aorta and illiac vessels. In Mettler: Essentials of radiology (2nd ed.). Philadelphia, PA: Elsevier.
17. Pawlotsky, J. M. (2004). Pathophysiology of Hepatitis C virus infection and related liver disease. TRENDS in Microbiology, 12(2), 96-102.
18. Ripamonti, R., Ferral, H., Alonzo, M., & Patel, N. (2006). Transjugular intrahepatic portosystemic shunt-related complications and practical solutions. Seminars in Interventional Radiology, 23(2), 165-176.
19. Schwartz, J., Beymer, C., Althaus, S., Larson, A., Zaman, A., Glickerman, D., & Kowdley, K. (2003). Cardiopulmonary consequences of transjugular intrahepatic portosystemic shunts. Journal of Clinical Gastroenterology, 38(7), 590-594.
20. Van der Heijde, R. M. J. L., Lameris, J. S., van den Berg, B., Wagenvoort, C. A., Hilvering, C., & van Buuren, H. R. (1996). Pulmonary hypertension after transjugular intrahepatic portosystemic shunt (TIPS). European Respiratory Journal, 9, 1562-1564.
21. Van der Linden, P., Le Moine, O., Ghysels, M., Ortinez, M., & Deviere, J. (1996). Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: Effects on right ventricular function. Hepatology, 23(5), 982-987.